HPV vaccine to prevent precancerous lesions from returning
Treatments studied
Part of Cancer, Ear, nose & throat, Infections, Women’s health & pregnancy clinical trials.
This trial tests whether an HPV vaccine (the nonavalent type) can help prevent the same precancerous lesions from coming back after treatment. It is for people who currently have a high-grade HPV-related lesion but have not yet been treated for it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 55 years old, regardless of gender identity.
- You must have a high-grade precancerous lesion (HSIL) caused by HPV, confirmed by biopsy.
- You cannot have had any prior HPV vaccination.
- You cannot have had a cancer caused by HPV (like anal, genital, or head and neck cancer).
- You cannot have received treatment for this precancerous lesion before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether getting the HPV vaccine after treatment for vulvar high-grade lesions can help prevent the lesions from coming back. It is for women who have not been vaccinated before and are about to have treatment for this condition.
This trial tests a new vaccine (SYS6026) for women with high-grade cervical lesions caused by HPV type 16 or 18. It aims to see if the vaccine can help the body clear these precancerous cells, potentially avoiding surgery.
This trial tests a new vaccine (pBI-11) given with a device that uses mild electric pulses to help the vaccine enter cells. It is for people who have HPV16 or 18 but no high-grade cervical changes.
This trial tests whether an HPV vaccine (Gardasil 9) can help women over 45 who still have HPV after treatment for a high-grade cervical lesion. It compares vaccinated and unvaccinated patients to see if vaccination lowers the risk of the lesion coming back.
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
This trial is testing a new vaccine designed to help your immune system fight cervical cancer caused by HPV types 16 or 18. It is for women who are receiving standard treatment like surgery, chemotherapy, or radiation.
Hear when a new Patients With Primary HPV High-grade Squamous Intra-epithelial Lesions (HSIL) at Vulvar Site trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.